Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Differential expression of anterior gradient protein 3 in intrahepatic cholangiocarcinoma and hepatocellular carcinoma

V. Brychtova, V. Zampachova, R. Hrstka, P. Fabian, J. Novak, M. Hermanova, B. Vojtesek,

. 2014 ; 96 (3) : 375-381.

Language English Country United States

Document type Journal Article, Research Support, Non-U.S. Gov't

Persistent link   https://www.medvik.cz/link/bmc14074232

Grant support
NT13794 MZ0 CEP Register

Intrahepatic cholangiocarcinoma (ICC) is the second most common primary liver cancer next to hepatocellular carcinoma (HCC). Despite the significant difference of the therapeutic strategy for both diseases, their histological appearance may be very similar. Thus the correct diagnosis is crucial for treatment choice but is often difficult to achieve. The aim of our study was to evaluate anterior gradient 3 (AGR3) as a new diagnostic marker helping to distinguish between ICC and HCC. AGR3 is a putative transmembrane protein implicated in breast, prostate and ovary tumorigenesis and belongs to the family of protein disulfide isomerases. Since there is little information on how AGR3 is expressed in normal and diseased tissues and what its exact function is, we analyzed its expression pattern in normal liver and tumor tissue of ICC and HCC. The immunohistochemical analysis in normal tissue revealed specific AGR3 expression in intrahepatic bile duct cholangiocytes which was not present in liver hepatocytes. Consequently we analyzed AGR3 expression in 74 representative samples of puncture biopsies, tissue excisions and resection specimens from which 48 samples were diagnosed as HCC and 26 as ICC. Our results showed AGR3 expression negative and weakly positive respectively in hepatocellular carcinomas compared to stronger AGR3 positivity in cholangiocellular carcinomas. AGR3 expression statistically significantly correlated to acid mucopolysaccharide expression and negatively correlated to glypican-3 expression. We conclude that according to receiver operating characteristics (ROC) analysis AGR3 expression is relatively specific for ICC and is potentially linked to mucosecretion, which may indicate potential implication in treatment resistance.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc14074232
003      
CZ-PrNML
005      
20191021135047.0
007      
ta
008      
141006s2014 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.yexmp.2014.04.002 $2 doi
035    __
$a (PubMed)24747240
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Brychtová, Veronika $u Regional Centre for Applied Molecular Oncology, Masaryk Memorial Cancer Institute, Zluty kopec 7, 65653 Brno, Czech Republic. $7 xx0228678
245    10
$a Differential expression of anterior gradient protein 3 in intrahepatic cholangiocarcinoma and hepatocellular carcinoma / $c V. Brychtova, V. Zampachova, R. Hrstka, P. Fabian, J. Novak, M. Hermanova, B. Vojtesek,
520    9_
$a Intrahepatic cholangiocarcinoma (ICC) is the second most common primary liver cancer next to hepatocellular carcinoma (HCC). Despite the significant difference of the therapeutic strategy for both diseases, their histological appearance may be very similar. Thus the correct diagnosis is crucial for treatment choice but is often difficult to achieve. The aim of our study was to evaluate anterior gradient 3 (AGR3) as a new diagnostic marker helping to distinguish between ICC and HCC. AGR3 is a putative transmembrane protein implicated in breast, prostate and ovary tumorigenesis and belongs to the family of protein disulfide isomerases. Since there is little information on how AGR3 is expressed in normal and diseased tissues and what its exact function is, we analyzed its expression pattern in normal liver and tumor tissue of ICC and HCC. The immunohistochemical analysis in normal tissue revealed specific AGR3 expression in intrahepatic bile duct cholangiocytes which was not present in liver hepatocytes. Consequently we analyzed AGR3 expression in 74 representative samples of puncture biopsies, tissue excisions and resection specimens from which 48 samples were diagnosed as HCC and 26 as ICC. Our results showed AGR3 expression negative and weakly positive respectively in hepatocellular carcinomas compared to stronger AGR3 positivity in cholangiocellular carcinomas. AGR3 expression statistically significantly correlated to acid mucopolysaccharide expression and negatively correlated to glypican-3 expression. We conclude that according to receiver operating characteristics (ROC) analysis AGR3 expression is relatively specific for ICC and is potentially linked to mucosecretion, which may indicate potential implication in treatment resistance.
650    _2
$a mladiství $7 D000293
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    _2
$a senioři nad 80 let $7 D000369
650    _2
$a žlučové cesty intrahepatální $x metabolismus $x patologie $7 D001653
650    _2
$a hepatocelulární karcinom $x diagnóza $x genetika $7 D006528
650    _2
$a transportní proteiny $x genetika $x metabolismus $7 D002352
650    _2
$a cholangiokarcinom $x diagnóza $x genetika $7 D018281
650    _2
$a diferenciální diagnóza $7 D003937
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a genetické markery $7 D005819
650    _2
$a glypikany $x genetika $x metabolismus $7 D053673
650    _2
$a lidé $7 D006801
650    _2
$a nádory jater $x diagnóza $x genetika $7 D008113
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a nádorové proteiny $x genetika $x metabolismus $7 D009363
650    _2
$a nádorové biomarkery $x genetika $x metabolismus $7 D014408
650    _2
$a mladý dospělý $7 D055815
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Žampachová, Víta $u First Department of Pathological Anatomy, Medical Faculty of Masaryk University and St. Anne's University Hospital, Pekarska 53, 65691 Brno, Czech Republic. $7 xx0088518
700    1_
$a Hrstka, Roman $u Regional Centre for Applied Molecular Oncology, Masaryk Memorial Cancer Institute, Zluty kopec 7, 65653 Brno, Czech Republic. $7 xx0077297
700    1_
$a Fabian, Pavel $u Department of Pathology, Masaryk Memorial Cancer Institute, Zluty kopec 7, 65653 Brno, Czech Republic. $7 xx0041823
700    1_
$a Novák, Jiří, $u Department of Comprehensive Oncology Care, Masaryk Memorial Cancer Institute, Zluty kopec 7, 65653 Brno, Czech Republic. $d 1959- $7 xx0071152
700    1_
$a Hermanová, Markéta, $u First Department of Pathological Anatomy, Medical Faculty of Masaryk University and St. Anne's University Hospital, Pekarska 53, 65691 Brno, Czech Republic. $d 1969- $7 xx0073982
700    1_
$a Vojtěšek, Bořivoj, $u Regional Centre for Applied Molecular Oncology, Masaryk Memorial Cancer Institute, Zluty kopec 7, 65653 Brno, Czech Republic. Electronic address: vojtesek@mou.cz. $d 1960- $7 xx0001694
773    0_
$w MED00001738 $t Experimental and molecular pathology $x 1096-0945 $g Roč. 96, č. 3 (2014), s. 375-381
856    41
$u https://pubmed.ncbi.nlm.nih.gov/24747240 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20141006 $b ABA008
991    __
$a 20191021135520 $b ABA008
999    __
$a ok $b bmc $g 1042115 $s 873144
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2014 $b 96 $c 3 $d 375-381 $i 1096-0945 $m Experimental and molecular pathology $n Exp Mol Pathol $x MED00001738
GRA    __
$a NT13794 $p MZ0
LZP    __
$a Pubmed-20141006

Find record

Citation metrics

Archiving options